Akari Therapeutics Files Key Patent for RNA Splicing ADC Payload
Event summary
- Akari Therapeutics filed a PCT patent application (PCT/US2026/45955) for its PH1 payload, targeting RNA splicing in cancers.
- The patent covers PH1's ability to disrupt multiple cancer-driving pathways beyond traditional cytotoxic mechanisms.
- PH1 demonstrated effects on angiogenesis, programmed cell death, and hormone signaling in preclinical studies.
- Akari aims to initiate a First-In-Human trial for its lead candidate, AKTX-101, by mid-2027.
The big picture
Akari's patent filing underscores the growing interest in RNA splicing as a therapeutic target in oncology. The company's approach diverges from traditional ADCs by focusing on spliceosome modulation, potentially offering a broader mechanism of action against resistant tumors. The expansion of its IP portfolio positions Akari to compete with established players in the ADC space, particularly as it advances toward clinical trials.
What we're watching
- Clinical Timing
- Whether Akari can meet its mid-2027 target for the First-In-Human trial of AKTX-101.
- IP Strategy
- How the company will leverage this patent to differentiate its ADC platform in a competitive oncology landscape.
- Preclinical Validation
- The pace at which PH1's preclinical findings translate into clinical efficacy across multiple cancer types.
Related topics